Payment overview · 2025
General Payments
$207.08
6 reported records · 3 companies
Healthcare provider profile · identity verified
Denis Kamberov, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MANSFIELD, LA · NPI 1932188422
Verified facts
What the public records show
CMS Open Payments records show Denis Kamberov, MD received $207.08 in general payments during 2025 across 6 reported records.
Amgen Inc. accounted for 60.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 60.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.53 | 23.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.55 | 16.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.08 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.53 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.55 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
174 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 178 |
| Amlodipine Besylate | Amlodipine Besylate | 697 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 548 | 107 |
| Metformin Hcl | Metformin Hcl | 473 | 105 |
| Losartan Potassium | Losartan Potassium | 452 | 105 |
| Omeprazole | Omeprazole | 390 | 92 |
| Carvedilol | Carvedilol | 316 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 303 | 125 |
| Lisinopril | Lisinopril | 295 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 49 |
| Gabapentin | Gabapentin | 263 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 251 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 56 |
| Meloxicam | Meloxicam | 211 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 188 | 65 |
| Allopurinol | Allopurinol | 186 | 36 |
| Jardiance | Empagliflozin | 186 | 35 |
| Furosemide | Furosemide | 185 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 37 |
| Eliquis | Apixaban | 174 | 26 |
| Sertraline Hcl | Sertraline Hcl | 169 | 35 |
| Januvia | Sitagliptin Phosphate | 156 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 45 |
| Potassium Chloride | Potassium Chloride | 152 | 29 |
| Simvastatin | Simvastatin | 148 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 31 |
| Farxiga | Dapagliflozin Propanediol | 117 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 45 |
| Trazodone Hcl | Trazodone Hcl | 113 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 100 |
| Metformin Hcl Er | Metformin Hcl | 99 | 22 |
| Donepezil Hcl | Donepezil Hcl | 98 | 16 |
| Azithromycin | Azithromycin | 95 | 81 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 18 |
| Montelukast Sodium | Montelukast Sodium | 89 | 17 |
| Ozempic | Semaglutide | 86 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 81 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 77 | 19 |
| Levetiracetam | Levetiracetam | 76 | suppressed |
| Spironolactone | Spironolactone | 75 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 34 |
| Linzess | Linaclotide | 73 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | suppressed |
| Memantine Hcl | Memantine Hcl | 66 | 14 |
| Clonazepam | Clonazepam | 65 | 14 |
| Digoxin | Digoxin | 65 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 19 |
| Glipizide | Glipizide | 64 | 19 |
| Finasteride | Finasteride | 61 | suppressed |
| Atenolol | Atenolol | 60 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 16 |
| Methylprednisolone | Methylprednisolone | 58 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 15 |
| Tramadol Hcl | Tramadol Hcl | 57 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | 12 |
| Sucralfate | Sucralfate | 53 | 13 |
| Nifedipine Er | Nifedipine | 52 | 15 |
| Valsartan | Valsartan | 52 | suppressed |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 13 |
| Enalapril Maleate | Enalapril Maleate | 49 | 12 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 12 |
| Famotidine | Famotidine | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 31 | 25 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Novolin R | Insulin Regular, Human | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 17 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 16 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Ethosuximide | Ethosuximide | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.08 · 6 records | Amgen Inc. | ABRYSVO, COMIRNATY, FARXIGA, PREVNAR 20, REPATHA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error